Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Checklists · ESMO GROW

ESMO GROW Is a Real Oncology Reporting Guideline. “GROW” Stands for Guidance for Reporting Oncology real-World evidence — Not Professional Growth

ESMO-GROW is a genuine, peer-reviewed, EQUATOR-listed reporting guideline for oncology real-world evidence studies — 35 items across six sections — published by the European Society for Medical Oncology in 2023. It has nothing to do with clinician professional development.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published8 October 2026 Last checked8 October 2026 Reading time7 minutes

Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, and colleagues, for ESMO, published “ESMO Guidance for Reporting Oncology real-World Evidence (GROW)” in Annals of Oncology in 2023, with an official checklist PDF, flowchart template and interactive tool hosted directly on ESMO’s own “Scales and Tools” page. It is oncology’s first dedicated reporting standard for registry, electronic-health-record and claims-data studies, built because general observational-reporting guidelines such as STROBE and RECORD were not tailored to oncology-specific issues like treatment-line sequencing and confounding by indication.

What it is

Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, et al. “ESMO Guidance for Reporting Oncology real-World Evidence (GROW).” Annals of Oncology, 2023 (PMID 37848160). Hosted by ESMO at esmo.org/scales-and-tools, and independently indexed on the EQUATOR Network.

Real-world evidence studies in oncology — registries, electronic health records, claims data — have grown rapidly but lacked a dedicated, oncology-specific reporting standard; general observational guidelines were not built around issues distinctive to oncology real-world data, such as treatment-line sequencing, confounding by indication, and the growing use of AI/machine-learning analysis methods.

Observational, real-world evidence studies in oncology, using registries, electronic health records, claims data or similar non-trial sources to answer questions about cancer treatment, outcomes or epidemiology, including those using AI/machine-learning methods. It is not for interventional, randomised oncology trials.

Is this the right tool?

Use it when

Oncology researchers and medical writers preparing a manuscript from real-world oncology data; journal editors and peer reviewers assessing oncology RWE submissions; systematic reviewers appraising the reporting quality of included oncology RWE studies.

Not the right tool when

Not for randomised controlled oncology trials — those use CONSORT (and SPIRIT for protocols). Not a substitute for STROBE or RECORD outside oncology. Not a treatment guideline and not a clinician professional-development framework — a live page describing it that way, with four “pillars” built around guideline-based practice, research, collaboration and well-being, has the wrong instrument entirely.

The 35 items, in six sections

Each item in the official tool is rated fully reported, partially reported, not reported, or not applicable.

Title, Introduction, Results, Discussion, Final considerations

ItemWhat it requires
Title (1 item)Signal the study type as real-world/observational, the population, data source, and outcomes of interest.
Introduction (3 items)Scientific rationale, the evidence gap the real-world study addresses, and the specific study aims.
Results (3 items)Participant flow and exclusions; baseline characteristics; primary and exploratory outcome results.
Discussion and conclusions (4 items)Findings in context of existing evidence; strengths and limitations; generalisability; implications for practice, policy or future research.
Final considerations (2 items)Funding and sponsorship disclosure; acknowledgements, author disclosures and contributions.

Methods (22 items — the largest section)

ItemWhat it requires
Objectives, design, data, variablesResearch question(s), study design, eligibility criteria, data-source description, data-management procedures, variable definitions, and bias-mitigation steps.
Statistical analysis and AI methodsThe statistical analysis plan, sample-size considerations, pre-specified vs. post hoc analyses, validity/sensitivity analyses, and, where machine-learning methods are used, data-preprocessing and model-explainability reporting.

Applying it, with the evidence

Real-world evidence studies in oncology are increasingly used to support regulatory and reimbursement decisions, but have historically varied enormously in how they report data provenance, cohort definition, and confounding control, making it hard to judge their reliability — the specific, documented gap ESMO-GROW was created to close, since general observational guidelines were never tailored to oncology real-world data.

Oncology real-world evidence studies specifically: registry-based outcomes research, claims-data and EHR-based treatment-pattern studies, and real-world comparative-effectiveness studies used to supplement or substitute for RCT evidence in cancer drug development and reimbursement decisions.

In order

Download the official checklist or use the interactive tool at the drafting stageNot only before submission — via esmo.org/scales-and-tools or grow.esmo.org.
Work through all 35 items section by sectionDrafting or revising the corresponding manuscript text as each item is addressed.
Give the Methods section particular attention22 of the 35 items sit there, concentrating oncology-RWE-specific bias-mitigation and, where relevant, AI/ML methodology reporting.
Build the companion GROW flowchartDocumenting participant/data flow, analogous to a CONSORT diagram but adapted for real-world data sources.
Distinguish prespecified analyses from post hoc ones explicitlyGROW requires this distinction given real-world evidence’s susceptibility to data-driven analysis choices.

Where it goes right

With it — no verifiable example found

Our research for this page did not turn up a named, checkable published paper that explicitly credits this checklist for a well-reported study. Rather than invent one, we are saying so. If you know of one, the EQUATOR Network page for this guideline is the place such examples tend to get collected.

Common mistakes

  • Not distinguishing prespecified from post hoc analyses is a common, GROW-specific gap. State explicitly which analyses were planned in advance.
  • Confounding by indication and treatment-line sequencing are routinely under-reported in oncology RWE. GROW’s Methods section is built specifically to surface this.
  • Omitting model explainability and preprocessing detail where AI/ML methods are used is a frequent, checklist-specific gap. Report both explicitly when machine-learning analysis is part of the study.

Where it falls short

Without it — no verifiable example found

We did not find a published audit naming specific papers that skipped this checklist. That is a gap in what is easy to find, not evidence that omission is rare.

Common questions

It is real: officially published by ESMO, hosted on ESMO’s own Scales and Tools page, backed by a 2023 Annals of Oncology publication (PMID 37848160), and independently indexed on the EQUATOR Network.

Guidance for Reporting Oncology real-World evidence. The ESMO prefix identifies the issuing society, so the full name is commonly written ESMO-GROW. It has no connection to clinician professional growth, guideline-based practice pillars, or well-being frameworks.

No. It is specifically for real-world, observational studies in oncology. Randomised oncology trials should use CONSORT for reports and SPIRIT for protocols instead.

References and sources

  1. Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, et al. ESMO Guidance for Reporting Oncology real-World Evidence (GROW). Annals of Oncology, 2023. read 8 October 2026. pubmed.ncbi.nlm.nih.gov/37848160
  2. ESMO. ESMO Guidance for Reporting Oncology real-World Evidence (ESMO-GROW). read 8 October 2026. esmo.org

Each source carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 8). ESMO GROW Is a Real Oncology Reporting Guideline. “GROW” Stands for Guidance for Reporting Oncology real-World evidence — Not Professional Growth. Pubrica. https://pubrica.com/insights/checklist/esmo-grow-checklist-introduction/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Pubrica AcademyWritten and maintained by the subject matter experts of Pubrica who do this work. Articles are revised when the standard underneath them moves, and each one carries the date it was last checked.

How Pubrica helps

Pubrica’s oncology medical-writing team works through all 35 ESMO-GROW items at the drafting stage, with particular attention to distinguishing prespecified from post hoc analyses in Methods.

Find something else

Search the rest of the Academy.

Open with no account. Type what you are working on, or open the full library to filter by category, sub-topic or resource type.

Send us the oncology real-world evidence study you are reporting.

A scoping read costs nothing and takes two business days. You get a written view of what the work needs and who would hold it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.